Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune MicroenvironmentNicholas Denton, Timothy P. Cripe, Thomas R. Scott et al.|Molecular Therapy — Oncolytics|2018Cited by 56
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenTimothy P. Cripe, Gregory K. Friedman, Chun‐Yu Chen et al.|Molecular Therapy — Oncolytics|2015Cited by 22
Characterization of MHC Class I and β‐2‐Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune‐Based Therapeutic TrialsKellie B. Haworth, Timothy P. Cripe, Michael Arnold et al.|Pediatric Blood & Cancer|2015Cited by 16
Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in childrenGregory K. Friedman, Timothy P. Cripe, Elizabeth A. Beierle et al.|Molecular Therapy — Oncolytics|2015Cited by 13
518. Tumor Associated Macrophages Mitigate Oncolytic Herpes Simplex Virus Efficacy in Part Through TGF-β SignalingNicholas Denton, Timothy P. Cripe, Chun‐Yu Chen et al.|Molecular Therapy|2016Cited by 1